Dror Bashan Purchases 56,000 Shares of Protalix BioTherapeutics (NYSE:PLX) Stock

Protalix BioTherapeutics, Inc. (NYSE:PLX) CEO Dror Bashan purchased 56,000 shares of the business’s stock in a transaction dated Friday, December 19th. The shares were purchased at an average cost of $1.81 per share, for a total transaction of $101,360.00. Following the purchase, the chief executive officer directly owned 188,516 shares of the company’s stock, valued at $341,213.96. This trade represents a 42.26% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Protalix BioTherapeutics Stock Up 0.6%

Shares of PLX stock opened at $1.76 on Thursday. The firm has a market cap of $141.54 million, a price-to-earnings ratio of -13.54 and a beta of -0.25. Protalix BioTherapeutics, Inc. has a 12 month low of $1.32 and a 12 month high of $3.10. The stock has a 50-day moving average price of $1.97 and a 200 day moving average price of $1.79.

Institutional Trading of Protalix BioTherapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Cascade Financial Partners LLC bought a new position in Protalix BioTherapeutics during the 2nd quarter worth approximately $25,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in Protalix BioTherapeutics in the second quarter worth $27,000. Bank of America Corp DE boosted its position in shares of Protalix BioTherapeutics by 364,766.7% during the second quarter. Bank of America Corp DE now owns 21,892 shares of the company’s stock worth $32,000 after purchasing an additional 21,886 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of Protalix BioTherapeutics by 126.5% during the third quarter. BNP Paribas Financial Markets now owns 15,215 shares of the company’s stock worth $34,000 after purchasing an additional 8,498 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Protalix BioTherapeutics in the 3rd quarter valued at $37,000. 16.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reduced their price objective on shares of Protalix BioTherapeutics from $15.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, November 21st. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, Protalix BioTherapeutics has a consensus rating of “Buy” and an average target price of $12.00.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics (NYSE:PLX) is a clinical‐stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost‐effective and scalable manner. Protalix’s core expertise lies in engineering plant cells to generate high‐quality therapeutic proteins for rare and specialty diseases.

The company’s first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.